RT Journal Article
SR Electronic
T1 Examination of Influenza A Infection Rate, Its Determinants, and Seasonal Influenza Vaccine Effectiveness in the Post-COVID-19 Pandemic Era
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.08.23292128
DO 10.1101/2023.07.08.23292128
A1 Wagenhäuser, Isabell
A1 Mees, Juliane
A1 Reusch, Julia
A1 Lâm, Thiên-Trí
A1 Schubert-Unkmeir, Alexandra
A1 Krone, Lukas B.
A1 Frey, Anna
A1 Kurzai, Oliver
A1 Frantz, Stefan
A1 Dölken, Lars
A1 Liese, Johannes
A1 Gabel, Alexander
A1 Petri, Nils
A1 Krone, Manuel
YR 2023
UL http://medrxiv.org/content/early/2023/07/12/2023.07.08.23292128.abstract
AB In the context of the COVID-19 pandemic, a pronounced wave of Influenza A occurred in the 2022/23 winter season under generally relaxed post-pandemic non-pharmaceutical preventive measures.Aim This study aimed to investigate the Influenza A infection rate, factors influencing its occurrence and seasonal Influenza vaccine effectiveness on seroconversion in the post-COVID-19 pandemic era.Methods The seroconversion of Anti-Influenza-A-Nucleoprotein/Matrix IgG was investigated in 402 healthcare workers (HCWs) during the winter season of 2022/2023 (23 May 2022 to 11 May 2023). The participants provided a serum sample and completed a study questionnaire both before and after the seasonal Influenza A wave (24 October 2022 to 8 January 2023). The levels of a vaccine-independent Anti-Influenza-A-Nucleoprotein/Matrix IgG were measured using the SERION ELISA classic Influenza A IgG assay, with a 2-fold increase as indicative of seroconversion after asymptomatic or symptomatic influenza infection.Results Among the participants, 20.6% (95% CI 17.0-24.9%; 83/402) showed seroconversion. The multivariate logistic regression analysis revealed that the age category of ≥ 45 years (p=0.03) and regular patient contact (p=0.02) significantly influenced seroconversion. However, the factors male gender, BMI, smoking, household size, seasonal Influenza vaccination, and SARS-CoV-2 infection during the Influenza A season were not significantly associated with seroconversion. The effectiveness of the 2022/23 seasonal Influenza vaccine on seroconversion induced by Influenza infection was 22.6% (95% CI -17.1-50.6%).Conclusion During the initial Influenza A season following the COVID-19 pandemic, approximately 20% of HCWs contracted an Influenza A infection. This highlights a potential risk and a significant asymptomatic or symptomatic infection rate posing a theoretical risk for intrahospital transmission chains and nosocomial infections.Competing Interest StatementManuel Krone receives honoraria from Abbott, GSK and Pfizer outside the submitted work. All other authors declare no potential conflicts of interest.Funding StatementThis study was partially funded by the German Federal Ministry of Education and Research (BMBF) as part of the Network University Medicine (NUM): NaFoUniMedCovid19 Grant No: 01KX2021, Project: Bundesweites Forschungsnetz Angewandte Surveillance und Testung (B-FAST). The study was further supported by the Free State of Bavaria with COVID-research funds provided to the University of Würzburg, Germany. Lukas B. Krone is supported by the Wellcome Trust (grant-No 203971/Z/16/Z) and Hertford College, Oxford, UK. Nils Petri is supported by the German Research Foundation (DFG) funded scholarship UNION CVD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics committee of the University of Würzburg in accordance with the Declaration of Helsinki (file no. 79/21).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAdditional data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) as well as the study protocol, statistical analysis plan, and analytic code is made available to researchers who provide a methodologically sound proposal to achieve aims in the approved proposal on request to the corresponding author.